![](/fileadmin/_processed_/csm_Ipsen_headquarters.__c__Ipsen_SA_865320fa5c.jpg)
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Under the agreement, Skyhawk will provide its discovery platform for RNA-targeting small molecules across several therapeutic areas, including rare...
![](/fileadmin/_processed_/csm_NOVo_New_434e85ba4f.png)
Obesity: reseachers switch on brown fat cells
The new discovery could herald a revolution in obesity research. If the principle discovered in male mice also applies in humans, therapeutics...
![](/fileadmin/_processed_/csm_Electrochea_process_c40cabeed1.png)
Electrochaea sells biomethane reactor to Again A/S
Like German bio-CH4 producer Electrochea GmbH, Danish Again A/S is using CO2-fxing archaea, but to manufacture carbon-negative chemicals such...
![](/fileadmin/_processed_/csm_Product_Award_winners_88844c23d2.png)
SLAS Europe 2024 honours products with most impact
Two companies were selected by the SLAS Europe 2024 jury from 13 applicants and six finalists as winners of this year's Product Award in Barcelona:...
![](/fileadmin/_processed_/csm_dollars-499481_1280-_Gerd_Altmann_pixabay_55a91b9ae7.jpg)
Forbion closes first Bioeconomy Fund with US$75m
Life Science investor Forbion opens a new sector for its lead partners who were eager to put money into industries within the ESG standards. At...
![](/fileadmin/_processed_/csm_Fundus_of_patient_with_retinitis_pigmentosa__mid_stage_10790b28cb.jpg)
Three companies launch gene therapy alliance for eye diseases
Today, the companies officially announced the launch of the GEAR partnership (Evaluation of Adeno-Associated Virus Vector Gene Therapy for the...
![](/fileadmin/_processed_/csm_EBC_c_CDC_7b5c041c11.png)
Hornet Therapeutics reports first data of EBV-triggered disease blocker
Hornet Therapeutics Ltd that was spun out in 2020 from the group of Christoph Hess (now University Cambridge) at University Basel, has...